DRAWINGS






Fig.2




Fig.3





Fig.5

Fig4



(C) (B) (A) Lck488-497 Lck486-494 antibody Lck208-216 None anti-CD3 anti-CD4 anti-CD8 anti-class I anti-class II anti-CD13 500 1000 500 1000 0 1000 0 500 0

Interferon-γ (pg/ml)

Fig.6





Fig.7







Fig.8

(A)



(B)




Fig.9 (B) (A) PBMC of cancer patient PBMC of cancer patient pre-stimulated with Lck208-216 pre-stimulated with none No peptide Lck208-216 Lck486-494 Lck488-497 250 50 100 150 200 40 60 80 100 20 0 Interferon- y (pg/ml) Interferon-y (pg/ml) (D) (C) PBMC of cancer patient PBMC of cancer patient pre-stimulated with Lck488-497 pre-stimulated with Lck486-494 No peptide Lck208-216 Lck486-494 Lck488-497 50 30 20 40 100 200 10

Interferon-γ (pg/ml)

Interferon- γ (pg/ml)

Fig.10

and the first state and the st




Fig.11

The state of the s





Fig.12



The second secon

14


1 - 1





the ten and the ten the ten

~, i


M. Stade there shall make their them












ŧ









The party of the state of the s

